AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04234321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal saline
Description: 0.9% Normal saline,20ml / 100cm2 / time,three times a day.
Study NCT01776775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal binder
Description: The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position.
Study NCT01209364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane is a device, methylprednisolone in a drug
Description: single intraarticular injection
Study NCT01209364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane is a device, methylprednisolone in a drug
Description: single intraarticular injection
Study NCT03938584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
Study NCT03938584 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
Study NCT04476433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ten Vida (10Vida)
Description: 10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
Study NCT03228589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic strain
Description: 8 weeks of treatment with probiotic strain
Study NCT03228589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of treatment
Study NCT04394104 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: No intervention is being administered.
Study NCT01172457 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Epiduroscopy with oxygen therapy
Description: Patients in this group will receive 30 mL of oxygen by epiduroscopy.
Study NCT01172457 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epiduroscopy with ozone therapy
Description: Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
Study NCT00506701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 40 mg tablet
Study NCT00882908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (R)
Description: Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
Study NCT00882908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
Study NCT00882908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PegIFNα-2a (P)
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
Study NCT00882908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a (P)
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
Study NCT00882908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
Study NCT00882908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
Study NCT01604655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary CT Angiography
Description: CCTA
Study NCT01604655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Test
Description: Stress Test
Study NCT04097496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act Out! Intervention
Description: Data included in the description of the intervention arm.
Study NCT03546504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procedure alteration and occupational therapy
Description: Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
Study NCT02130986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin level
Description: A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
Study NCT02130986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Results of procalcitonin (PCT) level to treating clinician
Description: In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.
Study NCT02130986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provide procalcitonin guideline to treating clinician
Description: Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (> 0.25-0.5 ug/L:3 days; > 0.5-1.0 ug/L:5 days; >1.0 ug/L:7 days). Physician follow-up is recommended.
Study NCT02130986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Visit
Description: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
Study NCT02130986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Visit
Description: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
Study NCT03698175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three good things exercise
Description: Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
Study NCT03698175 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo exercise
Description: Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
Study NCT04174651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
Study NCT04174651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Landscape Video
Description: Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
Study NCT03634371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Levothyroxine 150 mcg
Description: Administration of a 600 mcg levothyroxine dose
Study NCT03634371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eutirox 150 mcg
Description: Administration of a 600 mcg levothyroxine dose
Study NCT01463111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: Open label treatment per standard of care for bipolar disorder for six weeks.
Study NCT01463111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valproate
Description: Open label treatment per standard of care for bipolar disorder for six weeks.
Study NCT01463111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: Open label treatment per standard of care for bipolar disorder for six weeks.
Study NCT02995226 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires
Description: Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
Study NCT02995226 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
Description: Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
Study NCT02786316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT program
Description: HIT program for the rehabilitation of persons with NSCLBP
Study NCT02786316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation program
Description: a conventional rehabilitation program in persons with NSCLBP
Study NCT00195676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: adalimumab
Description: 40 mg every other week or 40 mg every week by subcutaneous injection
Study NCT00646529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)
Study NCT00818987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Open reduction internal fixation; reduction and immobilization
Study NCT00855907 — intervention group
Intervention type: OTHER
Intervention: clinical evaluation
Description: Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.
Study NCT02827331 — intervention group
Intervention type: OTHER
Intervention: Administrative and medical data
Description: * Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)
Study NCT00901576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503
Description: SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
Study NCT00901576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
Study NCT00901576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD503 + Concerta
Description: SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
Study NCT03423186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOBI003
Description: Weekly i.v.infusion
Study NCT01973595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds, Then no almonds
Description: Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
Study NCT02956850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
Study NCT02956850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: RO7020531 will be administered as per schedule specified in the respective arm.
Study NCT00392808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conjugated polysaccharide menC vaccine
Description: Booster vaccine dose at 14 to 18 months.
Study NCT01798641 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MIETHKE proGAV® / MIETHKE proSA®
Description: The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
Study NCT01798641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIETHKE proGAV® / MIETHKE proSA®
Description: The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
Study NCT00938977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Before and after effect of treatment with CPAP
Study NCT00938977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel Support Ventilation (Non-Invasive Ventilation)
Description: before/after effect of Bilevel support ventilation
Study NCT01406496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Three different timings of insulin delivered by a pump
Study NCT00440856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presentation of excised intervertebral disc fragments
Study NCT03950713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)
Description: The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
Study NCT04827797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balls
Description: Birth balls to exercise
Study NCT04349241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: favipiravir
Description: pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
Study NCT04349241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapy
Description: oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
Study NCT00247832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed motivation
Description: Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
Study NCT00247832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal motivational interviewing
Description: Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
Study NCT00027586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (STI571)
Description: 400 mg twice a day orally
Study NCT00951249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral of Partners
Description: Referral of up to five sexual partners by index participants for enrollment into the study
Study NCT00951249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening for STIs and counseling
Description: Identification of STIs and treatment or referral for treatment, if applicable
Study NCT00951249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer health care system navigators
Description: HIV/STI treatment and other medical and social services
Study NCT00951249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced counseling
Description: Counseling and referral for care offered to participants for issues such as substance use and mental health
Study NCT04348175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
Study NCT01718249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implantable neurostimulation system
Study NCT01416441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablets orally once daily.
Study NCT00151034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT00151034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00151034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00151034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00885768 — intervention group
Intervention type: PROCEDURE
Intervention: angiography
Description: all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
Study NCT04750980 — intervention group
Intervention type: OTHER
Intervention: food allergy
Description: food allergy
Study NCT04750980 — intervention group
Intervention type: OTHER
Intervention: respiratory allergy
Description: respiratory allergy
Study NCT04750980 — intervention group
Intervention type: OTHER
Intervention: healthy controls
Description: healthy controls
Study NCT01668641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Study NCT01668641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02757794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computerized cognitive remediation program
Description: a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
Study NCT02757794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard remediation
Description: A speech therapy and / or academic support is realized.
Study NCT03340896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
Study NCT03340896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
Study NCT03340896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
Study NCT03340896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
Study NCT03340896 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
Study NCT03340896 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Radiotherapy : 70Gy (2Gy/day) for 7 weeks.